A randomized study of the safety and pharmacokinetics of GSK3358699, a mononuclear myeloid‐targeted bromodomain and extra‐terminal domain inhibitor

AIMS: GSK3358699 is a mononuclear myeloid‐targeted bromodomain and extra‐terminal domain (BET) family inhibitor which demonstrates immunomodulatory effects in vitro. This phase 1, randomized, first‐in‐human study evaluated the safety, pharmacokinetics, and pharmacodynamics of GSK3358699 in healthy m...

Descripción completa

Detalles Bibliográficos
Autores principales: Brown, Jack A., Bal, Joanne, Simeoni, Monica, Williams, Peter, Mander, Palwinder K., Soden, Peter E., Daga, Shruti, Fahy, William A., Wong, Gabriel K., Bloomer, Jackie C., Erwig, Lars, Cui, Yi, Fernando, Disala, Carnaghan, Helen, Banham‐Hall, Edward J., Hopkins, Sarah, Davis, Bill G., Oliveira, Joao J. D., Prinjha, Rabinder K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300116/
https://www.ncbi.nlm.nih.gov/pubmed/34773923
http://dx.doi.org/10.1111/bcp.15137

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300116/
https://www.ncbi.nlm.nih.gov/pubmed/34773923
http://dx.doi.org/10.1111/bcp.15137

Ejemplares similares